About
Telix Pharmaceuticals Limited
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix’s lead investigational product, Illuccix
® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,
Telix and Monrol Expand Alliance to Include Lutetium Supply streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Telix and Monrol Expand Alliance to Include Lutetium Supply
MELBOURNE, Australia and ISTANBUL, Turkey, May 10, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered a global clinical supply agreement with Istanbul-based Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) for no carrier added (NCA) lutetium-177 (
177Lu), a key therapeutic isotope used in Telix’s portfolio of Molecularly Targeted Radiation (MTR) products.
This new activity expands an existing master services and distribution agreement concluded with Monrol in 2019 to support the ZIRCON Phase III trial of Telix’s TLX250-CDx (
89Zr-DFO-girentuximab) investigational product for imaging of renal cell carcinoma with positron emission tomography (PET). Under the terms of the agreement, Monrol will supply
Telix Pharmaceuticals Limited: Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a Phase III clinical trial of the Company s PSMA
1 targeted prostate cancer therapy candidate TLX591 (
177Lu-DOTA-rosopatamab), in patients with advanced metastatic castrate-resistant prostate cancer (mCRPC).
The Phase III ProstACT trial is an international, multi-centre, randomised controlled trial (RCT) in patients with PSMA-expressing mCRPC, experiencing disease progression following prior treatment with a novel androgen axis drug (NAAD). The ProstACT trial will enrol approximately 390 patients and incorporates patient selection using
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
Nachrichtenquelle: globenewswire | 10.05.2021, 01:13 | 108
1 MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a Phase III clinical trial of the Company’s PSMA
1 targeted prostate cancer therapy candidate TLX591 (
177Lu-DOTA-rosopatamab), in patients with advanced metastatic castrate-resistant prostate cancer (mCRPC). The Phase III “ProstACT” trial is an international, multi-centre, randomised controlled trial (RCT) in patients with PSMA-expressing mCRPC, experiencing disease progression following prior